Science
Remdesivir is more effective for COVID-19 than standard treatment – The Times Hub
Investing.com – A study by biotech company Gilead Sciences Inc (NASDAQ: GILD) found that a short, 5-day course of treatment of moderately severe hospitalized patients
Investing.com – A study by biotech company Gilead Sciences Inc (NASDAQ: GILD) found that a short, 5-day course of treatment of moderately severe hospitalized patients with COVID-19 with experimental remdesivir was more effective than 10 days and than standard treatment, writes Market Watch.
The results of the third phase of the open-label studies were published in the American scientific journal of the medical association JAMA. The company has already received permission for emergency use of …
-
Business17 hours agoCould a small investor today match the historic returns of Warren Buffett?
-
Noosa News15 hours agoQueensland government to set up $400m energy investment fund
-
Business11 hours agoAustralian rare earths companies trading at record levels as China tightens export controls
-
Business9 hours agoWhat’s Macquarie’s price target on Mineral Resources shares?